Topic: Cardiovascular risk - Primary Care
Monday, 12 September 2016
Two injectable antibody-based therapies inhibiting the activity of PCSK9 - alirocumab and evolucumab - have recently been licensed. This paper reviews the current status of lipid management, the actions of PCSK9, and the clinical trial results achieved with PCSK9 inhibitors in early studies.
Thursday, 02 February 2017
Offering smokers a taster session at an NHS Stop Smoking Service and explaining their personal risk of developing smoking-related diseases doubles their likelihood of attending a stop smoking course.
Friday, 02 August 2019
Community pharmacists are widely recognised as an under-utilised resource within the NHS, in spite of their skills and experience, and the accessibility of their premises. In recent years, community pharmacists have demonstrated the value of the clinical services they offer, particularly in the prevention of cardiovascular disease (CVD).
Thursday, 08 August 2019
In 2017 the University of Sheffield was commissioned by Public Health England (PHE) to develop a new return on investment (ROI) tool for cardiovascular disease (CVD) prevention, to be used by national and local decision-makers. The tool focuses on prevention of CVD in six key high-risk groups, identified through the NHS RightCare pathway as being currently underdiagnosed and insufficiently well managed. This includes patients with hypertension, diabetes (type 1 and type 2), non-diabetic hyperglycaemia, atrial fibrillation, chronic kidney disease and high cholesterol (the latter including patients with a QRISK2 score ≥ 10% or familial hypercholesterolaemia).
Monday, 08 April 2019
Our regular Evidence in Practice feature summarizes recent scientific papers focusing on different aspects of cardiovascular medicine. This month we feature recent research showing that anti-inflammatory biological drugs used to treat severe psoriasis have the potential to prevent heart in patients with the condition. Over one year of treatment, biological therapy improved coronary artery plaques in a manner similar to a low-dose statin.
Sunday, 12 March 2017
A new study questions the feasibility and value of primary care screening for peripheral arterial disease (PAD). The PIPETTE study is the first UK study of PAD prevalence for nearly a decade.
Wednesday, 04 April 2018
A new 5-minute procedure to scan blood vessels offers hope to claustrophobic patients unable to tolerate conventional magnetic resonance angiography (MRA) of blood vessels that can usually take between 30 minutes to one hour.
Tuesday, 27 February 2018
The prevalence of previously undetected dysglycaemia is high in patients who are free from cardiovascular disease but have one or two other risk factors (hypertension and/or dyslipidaemia). A new study shows that using the FINDRISC questionnaire as a first step of dysglycaemia screening does not provide any benefit in this population.
Wednesday, 04 April 2018
Addition of rivaroxaban to aspirin lowers major vascular events but increases major bleeding in patients with stable coronary artery disease. There was no signiﬁcant increase in intracranial bleeding or other critical organ bleeding. There was also a signiﬁcant net beneﬁt in favour of rivaroxaban plus aspirin and deaths were reduced by 23%.
Thursday, 27 October 2016
Semaglutide, an investigational human glucagon-like peptide-1 (GLP-1) analogue, significantly reduced the risk of the primary composite endpoint of time to first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction or non-fatal stroke by 26% vs placebo, when added to standard of care in adults with type 2 diabetes at high CV risk.